加味五虎追风散联合多巴丝肼片治疗帕金森病的疗效及对血清炎症因子水平的影响
|
摘要
目的:观察加味五虎追风散联合多巴丝肼片治疗帕金森病(PD)的疗效及对患者血清肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β及γ-干扰素(IFN-γ)水平的影响。方法:将160例PD患者随机分为治疗组和对照组各80例。对照组予多巴丝肼片治疗,治疗组在对照组基础上加用加味五虎追风散口服。两组疗程均为12周。比较两组临床疗效和治疗前后中医证候评分,统一帕金森病评分量表(UPDRS)、帕金森病生活质量量表(PDQ-39)、生活满意度(LSIB)评分及血清TNF-α、IL-1β、IFN-γ水平变化。结果:治疗组总有效率为91.25%,显著高于对照组的78.75%(P<0.05)。治疗后两组中医证候评分和UPDRS-Ⅱ、UPDRS-Ⅲ、UPDRS-Ⅳ评分及PDQ-39评分均较治疗前下降,且治疗组较对照组下降更明显(P<0.05)。治疗后两组LSIB评分较治疗前升高,且治疗组较对照组升高更明显(P<0.05)。治疗后两组血清TNF-α、IL-1β、IFN-γ水平均较治疗前明显下降,且治疗组较对照组下降更明显(P<0.05)。结论:加味五虎追风散联合多巴丝肼片治疗PD能更好地改善患者的运动症状,提高患者的生活质量,有效降低血清炎症因子水平。
引文
[1]Goswami P,Joshi N,Singh S.Neurodegenerative signaling factors and mechanisms in Parkinson’s pathology[J].Toxicology in Vitro An International Journal Published in Association with Bibra,2017,43:104-112.
[2]Ma C L,Su L,Xie J J,et al.The prevalence and incidence of Parkinson’s disease in China:a systematic review and metaanalysis.[J].Journal of Neural Transmission,2014,121(2):123-134.
[3]Calabrese V P.Projected number of people with parkinson disease in the most populous nations,2005 through 2030[J].Neurology,2007,69(2):223-224.
[4]王铭.帕金森病的药物治疗[J].中国医药指南,2014,12(1):48-49.
[5]张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409.
[6]隆呈祥.中医老年颤证诊断及疗效评定标准[J].北京中医学院学报,1992,15(4):39.
[7]Hoehn M M,Yahr M D.Parkinsonism:onset,progression and mortality[J].Neurology,2001,57(S3):11-26.
[8]Goetz C G,Colosimo C.Dyskinesia Rating Scales in Parkinson’s Disease[J].Springer London,2014,14(2):17-31.
[9]李慧娟,陈妙霞,胡爱玲,等.帕金森病患者生活质量影响因素调查分析[J].现代临床护理,2012,11(2):8-10.
[10]Romero J O,Padillo A A,Hernández F J B,et al.Utility of transcranial sonography in the diagnosis of drug-induced parkinsonism:a prospective study[J].European Journal of Neurology,2013,20(11):1451-1458.
[11]Bentea E,Verbruggen L,Massie A.The Proteasome Inhibition Model of Parkinson’s disease[J].Journal of Parkinson’s disease,2017,7(1):31.
[12]王刚,崔海伦,刘军,等.帕金森病发病机制及诊断与治疗转化研究进展[J].中国现代神经疾病杂志,2018,18(1):19-24.
[13]Teng L,Hong F,Zhang C,et al.Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson’s disease[J].Neural Regeneration Research,2014,9(4):407.
[14]余先凤.神经炎症与帕金森病关系的研究进展[D].蚌埠:蚌埠医学院,2015.
[15]唐玲,陈莉芬,余震.探讨帕金森病患者血液及脑脊液相关炎性因子的临床意义[J].中华老年心脑血管病杂志,2016,18(2):122-124.
[16]沈婕,李久胜.小胶质细胞在神经退行性疾病中的神经免疫调节作用[J].河南医学研究,2017,26(2):244-246.
[17]王敏,韩彦青,姜晓萌,等.吲哚胺2,3-二加氧酶抑制剂对慢性脑低灌注大鼠认知功能损害的行为学改善[J].中华老年心脑血管病杂,2015,17(5):526-529.
[2]Ma C L,Su L,Xie J J,et al.The prevalence and incidence of Parkinson’s disease in China:a systematic review and metaanalysis.[J].Journal of Neural Transmission,2014,121(2):123-134.
[3]Calabrese V P.Projected number of people with parkinson disease in the most populous nations,2005 through 2030[J].Neurology,2007,69(2):223-224.
[4]王铭.帕金森病的药物治疗[J].中国医药指南,2014,12(1):48-49.
[5]张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409.
[6]隆呈祥.中医老年颤证诊断及疗效评定标准[J].北京中医学院学报,1992,15(4):39.
[7]Hoehn M M,Yahr M D.Parkinsonism:onset,progression and mortality[J].Neurology,2001,57(S3):11-26.
[8]Goetz C G,Colosimo C.Dyskinesia Rating Scales in Parkinson’s Disease[J].Springer London,2014,14(2):17-31.
[9]李慧娟,陈妙霞,胡爱玲,等.帕金森病患者生活质量影响因素调查分析[J].现代临床护理,2012,11(2):8-10.
[10]Romero J O,Padillo A A,Hernández F J B,et al.Utility of transcranial sonography in the diagnosis of drug-induced parkinsonism:a prospective study[J].European Journal of Neurology,2013,20(11):1451-1458.
[11]Bentea E,Verbruggen L,Massie A.The Proteasome Inhibition Model of Parkinson’s disease[J].Journal of Parkinson’s disease,2017,7(1):31.
[12]王刚,崔海伦,刘军,等.帕金森病发病机制及诊断与治疗转化研究进展[J].中国现代神经疾病杂志,2018,18(1):19-24.
[13]Teng L,Hong F,Zhang C,et al.Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson’s disease[J].Neural Regeneration Research,2014,9(4):407.
[14]余先凤.神经炎症与帕金森病关系的研究进展[D].蚌埠:蚌埠医学院,2015.
[15]唐玲,陈莉芬,余震.探讨帕金森病患者血液及脑脊液相关炎性因子的临床意义[J].中华老年心脑血管病杂志,2016,18(2):122-124.
[16]沈婕,李久胜.小胶质细胞在神经退行性疾病中的神经免疫调节作用[J].河南医学研究,2017,26(2):244-246.
[17]王敏,韩彦青,姜晓萌,等.吲哚胺2,3-二加氧酶抑制剂对慢性脑低灌注大鼠认知功能损害的行为学改善[J].中华老年心脑血管病杂,2015,17(5):526-529.